Ed Pezalla, MD, MPH Vice President, Pharmaceutical Policy and Strategy, Aetna joined us at the World Orphan Drug Congress USA 2016 to facilitate discussions into the importance of approaching orphan drug discovery by starting with the unmet needs of payers and patients alike.
“It may sometimes seem as if cost is the only factor in formulary discussions but clinical and broader economic issues remain very important.”
Why identify these needs? This identification encourages technological innovation, highlights patient member issues, examines member retention and overall, improves the efficiency of the healthcare system as a whole.
Download Ed’s presentation to discover more about:
- Identifying unmet needs
- Drug development
- Orphan drugs* approved in 2014 by national priority
- Evaluating opportunities for achieving the Triple Aim
- Drug Development: establishing value by starting off on the right foot and following through
- Unmet need matrix
Join us at the NEW look World Orphan Drug Congress USA 2017, where scientific innovation meets commercialization >>